MedTrace Logo

Trial on the Safety and Efficacy of MLS-101 in Patients With Uncontrolled Hypertension

NCT05001945 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2024-01-05

Study results available
· View outcomes & findings →

Summary

A randomized, double-blind, placebo-controlled, dose-ranging, Phase II study to evaluate the safety, efficacy, and tolerability of MLS-101 in Subjects With Uncontrolled Hypertension

Conditions

  • Hypertension, Renal

Interventions

DRUG

MLS-101 (Part I)

MLS-101 tablet(s) by mouth once or twice daily.

OTHER

Placebo (Part I)

Placebo tablet(s) by mouth once or twice daily.

OTHER

Placebo (Part II)

Placebo tablet(s) by mouth once daily.

DRUG

MLS-101 (Part II)

MLS-101 tablet(s) by mouth once daily.

Sponsors & Collaborators

  • Mineralys Therapeutics Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-07-01
Primary Completion
2022-09-07
Completion
2022-10-07
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05001945 on ClinicalTrials.gov